Loading company financials…
NYSE · Pharmaceutical Preparations · CIK 0001821825
$13.78
+0.15% · delayed 15 min
$3.59B market value
What this company does
Organon & develops and makes medicines. It took in $6.22B last year, which makes it a mid-sized company. Of every dollar it sells, about 3 cents is left as profit.
A published bankruptcy-risk model places it in its distress range.
Altman Z-Score 1.20
These are things the company filed or that a published model flagged — not predictions, and not a reason on their own to buy or sell anything.
Financial health
A mixed picture — some clear strengths and some weaknesses.
From Organon & Co.'s FY2025 annual filing · share price scored separately
Every check behind the three models, and what each one tests
Measured against FY2024, from the 10-K
Deteriorated: -78.4%
$864.0M to $187.0M
Deteriorated: −4.7 pts
58.0% to 53.3%
Deteriorated: −10.5 pts
13.5%
It makes a profit rather than burning through money.
$187.0M earned last year
Day-to-day operations generate real cash, not just accounting profit.
$700.0M cash from operations
Sales are shrinking rather than growing.
down 2.9% on last year
It keeps less of each sale as profit than it did a year ago.
13.5% → 3.0%
Clearing its debt would take many years at the current rate of cash generation.
about 11.5 years of cash flow
A widely used bankruptcy-risk model places it in its distress range.
Altman Z 1.20
Filter by minute, hour, day or week
Loading price history…
Expectations
Not from the filings — what other people are betting on, and what the price already assumes.
The growth rate someone buying today is paying for, against what the company has delivered
At today's price, the market is paying for free cash flow to grow by about 7% a year for the next 10 years. Over the last 6 years it shrank by about 25% a year.
The essentials
Each answered from the filings, with the numbers behind it.
Yes. It keeps about 3 cents of every dollar of sales as profit, earning $187.0M last year.
What it earns, what it keeps, and what it costs to run — all from the same filing
Whether the dividend is covered by what the business actually earns
It pays out 47 cents of every dollar of profit and keeps the rest, which leaves the payment comfortably covered. It paid out 13% of the cash its operations generated. It has paid in each of the last 5 years.
GoodFigures from the FY2025 annual filing
Last year it earned $187.0M and generated $700.0M of cash from operations.
Reported annual figures
Insider activity, ownership stakes and what's coming — straight from EDGAR, before any article is written about it
Nothing recent
No insider trades, pending-sale notices or 5% stake filings from OGN in the last few months. That is the ordinary case, not a gap.
Not investment advice, and not a signal to act on by itself — a filing says what happened, not why, and insiders trade for ordinary reasons having nothing to do with where they think the company is headed.
Go deeper
Every figure above traces back to one of these filings.
Straight from SEC EDGAR — the original source for every figure above
| Filing | Filed | Covers to |
|---|---|---|
| Major event announcement(8-K) | 2026-07-31 | 2026-07-31 |
| Quarterly report(10-Q) | 2026-07-31 | 2026-06-30 |
Financial figures are from OGN's 10-K for fiscal year 2025 (period ending 2025-12-31), reported under the US GAAP taxonomy. View the source filing.
6 of 9 checks passed
Nine yes-or-no tests of whether this year's finances improved on last year's.
1.20
In the distress zone
For this model, above 2.99 is safe and below 1.81 is distress.
Distance from bankruptcy, from a model fitted on companies that did and did not go bust. It describes a balance sheet's shape today; it does not forecast a failure.
-2.65
Below the threshold — nothing unusual flagged
Scores above -1.78 are the ones the model associates with earnings manipulation.
Screens eight accounting ratios for the pattern earnings manipulators tend to leave. A flag is a reason to read the filing closely, never evidence of wrongdoing.
Every figure above comes from the FY2025 filing as filed with the SEC.
Deteriorated: -29.6%
$764.0M to $538.0M
Deteriorated: -15.0%
$675.0M to $574.0M
Changed: -7.4%
$175.0M to $162.0M
3 other measures barely moved. Figures compare the two most recent annual filings — read the latest one. Nothing here reads the management commentary, which is where a company explains its own numbers.
Discounted at 8%–10% a year, with growth settling to 2.5% after 10 years. Those rates are ordinary choices, not measurements: across that range the assumed growth works out between 4% and 9%. This describes what the price implies — it is not a forecast, and not a view on whether the price is right.
Measured on and published about a week later — this is a fortnightly snapshot, not a live position.
About 5.8% of this company's shares have been borrowed and sold by people expecting to buy them back cheaper. That is a bet the price falls. Those people can be wrong, and when a heavily shorted share rises they have to buy it back, which pushes it up further.
Collected by FINRA from broker-dealers twice a month. It counts positions, not intentions, and some of it is hedging rather than a directional bet against the company.
Nothing in this section is a figure this company reported about itself. These are expectations and positions — what the price implies, what analysts have published, what short sellers are betting, and what large funds held at the last count. WylthIQ reports them; it does not endorse them, does not forecast prices, and takes no view on whether any of them will turn out to be right.
No. Sales shrank 2.9% last year.
Yes. Clearing its debt would take roughly 11.5 years of cash flow. For every $1 it owes, it owns $1.06 in assets. A bankruptcy-risk model also places it in its distress range.
Around average. Investors pay $19.2 for every $1 of yearly profit.
Nothing unusual. Its accounting patterns look like those of companies that report earnings straightforwardly.
At a glance
| Major event announcement(8-K) | 2026-07-23 | 2026-07-23 |
| Major event announcement(8-K) | 2026-07-17 | 2026-07-17 |
| Major event announcement(8-K) | 2026-06-11 | 2026-06-09 |
| Quarterly report(10-Q) | 2026-05-04 | 2026-03-31 |
| Major event announcement(8-K) | 2026-04-30 | 2026-04-30 |
| Major event announcement(8-K) | 2026-04-27 | 2026-04-26 |
| Shareholder voting information(DEF 14A) | 2026-04-24 | 2026-06-09 |
| Annual report(10-K) | 2026-02-24 | 2025-12-31 |
| Major event announcement(8-K) | 2026-02-20 | 2026-02-20 |
| Major event announcement(8-K) | 2026-02-12 | 2026-02-12 |
| Quarterly report(10-Q) | 2025-11-10 | 2025-09-30 |
| Major event announcement(8-K) | 2025-11-10 | 2025-11-10 |
| Quarterly report (amended)(10-Q/A) | 2025-11-10 | 2025-06-30 |
| Quarterly report (amended)(10-Q/A) | 2025-11-10 | 2025-03-31 |
| Annual report (amended)(10-K/A) | 2025-11-10 | 2024-12-31 |
| Major event announcement(8-K) | 2025-11-07 | 2025-11-03 |
| Major event announcement (amended)(8-K/A) | 2025-10-30 | 2025-10-26 |
| Major event announcement(8-K) | 2025-10-27 | 2025-10-26 |
Coverage from the last 30 days
Arletta Pharma Solutions Appoints Jeannette Jager-van Dijk as Chief Executive Officer
Yahoo Finance ·
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know
Yahoo Finance ·
Organon & Co. Shareholders Clear Sun Pharma Merger Deal
Yahoo Finance ·
Organon (OGN) Names A Canada Chief, Is The Stock Cheap?
Yahoo Finance ·
Organon to Report Second Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing
Yahoo Finance ·
Orogen Royalties Acquires Two Gold Projects in Southwest Utah
Yahoo Finance ·
National Can-RISE Study to Help Close Critical Gaps in Menopause Research
Yahoo Finance ·
Orogen Royalties Announces Results of the 2026 Annual General Meeting
Yahoo Finance ·
Priori Expands Client Advisory Board with New Members from Fortune 500 Corporate Legal Departments
Yahoo Finance ·
Organon Opens REMS Program for MIUDELLA® Ahead of Anticipated Commercial Availability
Yahoo Finance ·
Compared to Estimates, Organon (OGN) Q2 Earnings: A Look at Key Metrics
Yahoo Finance ·
Organon (OGN) Lags Q2 Earnings Estimates
Yahoo Finance ·
Primary sources and further research